GlassScriptPhysician profile
Allison NP Sobin
NPI 1487152468
$5,879.31
in general payments reported to CMS, 2019-2025
36 companies · $314 in 2025
The $314 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $233 · 2022: $1,735 · 2023: $940 · 2024: $2,657 · 2025: $314.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,826 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,825.85 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,165.18 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Harmony Biosciences LLC | $493.92 | 2022-2024 | Wakix |
| Regeneron Healthcare Solutions, INC. | $493.10 | 2021-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $418.91 | 2021-2024 | Fasenra, Tezspire, Airsupra |
| Takeda Pharmaceuticals U.S.A., INC. | $383.07 | 2021-2024 | Glassia |
| Mylan Specialty L.P. | $281.44 | 2021-2024 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $278.43 | 2021-2024 | Ofev |
| Axsome Therapeutics, INC. | $251.26 | 2023-2024 | Sunosi |
| Jazz Pharmaceuticals INC. | $239.68 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $201.99 | 2021-2024 | |
| Genzyme Corporation | $177.40 | 2022-2024 | |
| Genentech USA, INC. | $163.03 | 2022-2024 | Xolair |
| Grifols USA, LLC | $161.16 | 2022-2024 | Prolastin-C Liquid |
| Philips North America LLC | $155.12 | 2021-2022 | |
| Baxter Healthcare | $131.80 | 2024 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $122.43 | 2022-2024 | Zerbaxa, Recarbrio, Belsomra |
| Amgen INC. | $83.18 | 2022-2024 | Tezspire |
| Intuitive Surgical, INC. | $76.53 | 2025 | |
| Electromed, INC. | $72.56 | 2022-2025 | Smartvest |
| United Therapeutics Corporation | $53.06 | 2022-2023 | Tyvaso |
| Vifor Pharma, INC. | $47.71 | 2024 | Zemaira |
| Inspire Medical Systems, INC. | $44.51 | 2024-2025 | Inspire |
| Teva Pharmaceuticals USA, INC. | $43.69 | 2022-2023 | Airduo Digihaler |
| Insmed, INC. | $40.06 | 2022-2024 | Arikayce |
| Verona Pharma, INC. | $36.89 | 2025 | Ohtuvayre |
| Mallinckrodt Hospital Products INC. | $34.74 | 2022 | |
| Avadel Cns Pharmaceuticals, LLC | $34.73 | 2024 | Lumryz |
| Idorsia Pharmaceuticals US INC | $32.95 | 2024 | Quviviq |
| Abbvie INC. | $29.28 | 2024 | |
| Paratek Pharmaceuticals, INC. | $20.66 | 2022 | |
| Gilead Sciences, INC. | $20.23 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $19.43 | 2023 | Uptravi, Opsumit |
| Janssen Pharmaceuticals, INC | $19.30 | 2022 | |
| Resmed Corp | $18.83 | 2024 | |
| Abbott Laboratories | $18.57 | 2024 | Freestyle Libre 3 |
| Azurity Pharmaceuticals, INC. | $14.48 | 2023 | Horizant |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Sobin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.